Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
×
Share this article
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
Share on print
Print

Lowering LDL-cholesterol reduces CV event risk in diabetic dyslipidaemia

Cardiovascular – October 2019 digest

LDL-cholesterol lowering reduces atherosclerotic cardiovascular disease event risk in statin-treated patients with type 2 diabetes and dyslipidaemia.

Rana JS, Liu JY, Moffett HH et al (2019) Risk of cardiovascular events in patients with type 2 diabetes and metabolic dyslipidemia without prevalent atherosclerotic cardiovascular disease. Am J Med Jul 22, 2019 [epub ahead of print] 

  • Patients with type 2 diabetes and dyslipidaemia are at high risk for atherosclerotic cardiovascular disease events. Statins are the mainstay of risk reduction but questions remain about the association between low-density lipoprotein (LDL) cholesterol levels and risk of incident atherosclerotic cardiovascular disease in this group of patients.
  • Investigators conducted an observational cohort study of 19,095 patients with type 2 diabetes, metabolic dyslipidaemia and high LDL-cholesterol who were taking stains but who did not have atherosclerotic cardiovascular disease. 
  • Patients (mean age 63.4 years) were followed up for 5.9 years and the rates of atherosclerotic cardiovascular disease stratified according to LDL-cholesterol categories.
  • The level of LDL-cholesterol achieved had no significant effect on unadjusted rates of atherosclerotic cardiovascular disease events. 
  • After adjusting for demographics and clinical characteristics, there was significantly lower risk of incident atherosclerotic cardiovascular disease events with decreasing LDL-cholesterol levels (P<0.0001). Individuals achieving LDL-cholesterol <50 mg/dl had the lowest level of risk.
  • It was concluded that lower LDL-cholesterol levels were associated with a lower risk of incident atherosclerotic cardiovascular disease events in statin-treated patients with type 2 diabetes and dyslipidaemia and that further evaluation of the benefits of achieving very low LDL-cholesterol in these patients was needed.

Click here to access the article in full

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.